• MedTech & Deep Tech Deal News 20 July

    Here is Matt Lowdon‘s weekly medtech, deeptech, and biotech funding summary. Headlines include updates across energy intel, AI DD, neurotech and more.

    πŸ”” Dimerix Limited snaps up Mission Therapeutics’s phase 2-ready kidney disease candidate in $292M deal.

     

    πŸ”” The British Business Bank commits Β£21m to EQT Group Life Sciences’ Health Economics 3 Fund to support scaling medical technology and digital health companies.

     

    πŸ”” Spirit Health raises Β£2m from Midlands Engine Investment Fund II

     

    πŸ”” Gaussion, the London-based deep tech company pioneering energy intelligence technology for battery packs, has secured a $28m investment round.

     

    πŸ”” Orakl Oncology has secured exclusive rights to four undisclosed oncology assets from Sanofi, giving the startup an opportunity to test whether its combination of patient-derived tumour models and artificial intelligence can improve drug development decisions.

     

    πŸ”” BIOTRONIK Neuro snaps up spinal cord stimulation portfolio from SOIN NEUROSCIENCE, INC. for next-gen pain project

     

    πŸ”” Resmed to sell MatrixCare for $490M to private equity firm

     

    πŸ”” Cambridge-based agtech startup Dogtooth Technologies has secured over Β£14m in growth capital to scale the commercial deployment of its AI-powered fruit-harvesting robots.

     

    πŸ”” Chai Discovery brews up $400M series C to fuel AI molecule models used by Lilly, Novartis and Pfizer

     

    πŸ”” Spanish investment holding company CriteriaCaixa plans to invest €300m in early-stage biotechnology and technology companies by 2030

     

    πŸ”” Austria’s GraphTx has raised $5m in new financing, bringing its total funding to more than $10m as it advances internal drug discovery programmes in inflammation and immunology built on its AI-enabled platform.

     

    πŸ”” Swedish biotech PharmNovo has raised about SEK39m to help finance a phase 2 study of PN6047, its experimental treatment for neuropathic pain.

     

    πŸ”” Alchemab Therapeutics Ltd extends Series A with Β£25m from British Business Bank

     

    πŸ”” Avere Therapeutics goes public via NextCure reverse merger, secures Hansoh IL-23 drug with $2.3B deal

     

    πŸ”” Welsh biotech Draig Therapeutics has raised an oversubscribed $65 million Series B to accelerate its neuropsychiatry pipeline, taking its total funding to $205 million

     

    πŸ”” Global investment giant KKR has launched Allyntra, a new precision-engineered solutions platform for the medtech industry, and announced several senior management changes.

     

    πŸ”” Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market

     

    Congratulations to all involved.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close